TransEnterix, a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance surgical robot at the 45th American Association of Gynecologic Laparoscopists (AAGL) Global Congress.
The congress will be held on November 16-18, 2016 in Orlando, FL.
The Senhance will be available for surgeon evaluations at the congress. Surgeons may schedule system evaluations by signing up at the TransEnterix booth. Dr. Salvatore Gueli Alletti from the Division of Gynecologic Oncology at the Catholic University of the Sacred Heart in Rome, Italy, will headline a special symposium dedicated to the clinical experience of the Senhance in Gynecologic Surgery.
The symposium will be held on the morning of Wednesday, November 16, 2016, and participants must register through the AAGL to attend.
The Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery but is not available for sale in the US. TransEnterix is preparing a 510(k) submission for the Senhance.
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.
The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform.
The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States.